Please ensure Javascript is enabled for purposes of website accessibility

Inovio Pharmaceuticals Lands $6.9 Million Grant to Fund a Clinical Trial for Its Coronavirus Vaccine

By Prosper Junior Bakiny - Apr 16, 2020 at 2:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company will collaborate with the International Vaccine Institute to conduct a phase 1/2 clinical trial for its investigational SARS-CoV-2 vaccine.

Inovio Pharmaceuticals (INO 6.08%) has been a leader in the race to develop a vaccine for SARS-CoV-2, the novel coronavirus that causes COVID-19. The company recently started a phase 1 clinical trial for its investigational vaccine, INO-4800. The trial will involve up to 40 healthy adult volunteers and will test the safety of INO-4800, as well as its ability to trigger an immune response in the body. Inovio expects to start collecting data from the trial by late summer.

Now, it's gearing up to start a phase 1/2 clinical trial in South Korea for the vaccine candidate with help from a $6.9 million grant it received from the Coalition for Epidemic Preparedness Innovations (CEPI). The biotech company will team up with the International Vaccine Institute -- which will lead the trial -- and the Korea National Institute of Health. Inovio's shares jumped by about 8% following this news.

Microscopic view of coronavirus.

Image Source: Getty Images.

This wasn't the first grant Inovio received to help fund its development of a SARS-CoV-2 vaccine. The company had previously won a grant of up to $9 million from the CEPI. Also, back in March, Inovio partnered with Ology Bioservices -- a privately held biotechnology company -- and the two had jointly received a grant of $11.9 million from the Department of Defense to expedite their ability to ramp up production of INO-4800. 

Given that there are at least 70 SARS-CoV-2 vaccine candidates currently in development, including three that are already in early-stage clinical trials, Inovio will need all the help it can get if it hopes to be the first company to demonstrate that its vaccine successfully prevents COVID-19. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$2.79 (6.08%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.